TRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report released on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a neutral rating on shares of TRACON Pharmaceuticals in a research note on Monday, July 1st.

TRACON Pharmaceuticals Price Performance

Shares of NASDAQ TCON opened at $0.13 on Friday. The stock has a market capitalization of $453,530.00, a PE ratio of 0.20 and a beta of 1.29. The business has a fifty day moving average price of $0.71 and a two-hundred day moving average price of $2.64. TRACON Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $14.75.

TRACON Pharmaceuticals (NASDAQ:TCON) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The business had revenue of $0.06 million during the quarter.

TRACON Pharmaceuticals Dividend Announcement

The firm also recently declared a dividend, which was paid on Monday, July 8th. Stockholders of record on Friday, June 28th were paid a $0.045 dividend. The ex-dividend date was Thursday, June 27th. This represents a dividend yield of 40.3%.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.